by Plus Therapeutics | Aug 14, 2025 | LM
Plus Therapeutics (NASDAQ: PSTV) presented encouraging data from a retrospective analysis of the CNSide® Cerebrospinal Fluid (CSF) Assay Platform at the 2025 Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference in...
by Plus Therapeutics | Aug 12, 2025 | LM
Leptomeningeal Metastases (LM) is a devastating complication of advanced cancers, where cancer cells spread to the cerebrospinal fluid and leptomeninges of the brain and spinal cord. Research and collaboration are critical to improving outcomes for patients facing...
by Plus Therapeutics | Aug 7, 2025 | GBM
Glioblastoma (GBM) is one of the most aggressive and challenging forms of brain cancer, with limited treatment options available today. At Plus Therapeutics (NASDAQ: PSTV), we are committed to developing new therapies that can bring hope to patients and their...
by Plus Therapeutics | Aug 6, 2025 | LM
Mark your calendars!Date: Thursday, August 14, 2025Time: 6:15 PM ESTLocation: Baltimore Waterfront Marriott, Baltimore, MD We are proud to invite you to a compelling educational symposium at the 2025 SNO/ASCO CNS Metastases Conference, where leading voices in...
by Plus Therapeutics | Aug 1, 2025 | LM
Today, on World Lung Cancer Day, we pause to recognize the strength of patients and survivors and to reflect on the critical need for continued research and innovation in lung cancer care. This annual observance shines a spotlight on the millions of people affected by...
Recent Comments